This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Jun 22;359(9324):2126-7.

doi: 10.1016/S0140-6736(02)09111-0.

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer

Affiliations

PMID: 12090973
DOI: 10.1016/S0140-6736(02)09111-0

Comment

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer

Peter Ravdin. Lancet. 2002.

. 2002 Jun 22;359(9324):2126-7.

doi: 10.1016/S0140-6736(02)09111-0.

Author

Affiliation

¹ Department of Medical Oncology, University of Texas Health Science Center, San Antonio, TX 98284-7884, USA. peter@oncology.uthscsa.edu

PMID: 12090973
DOI: 10.1016/S0140-6736(02)09111-0

No abstract available

PubMed Disclaimer

Comment on

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group. Baum M, et al. Lancet. 2002 Jun 22;359(9324):2131-9. doi: 10.1016/s0140-6736(02)09088-8. Lancet. 2002. PMID: 12090977 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information